Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Trastuzumab Rezetecan in Stage III Unresectable HER2-Positive NSCLC
NCT07778745Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
01
Overview
A Phase 2 trial of adebrelimab, trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimabtrastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07778745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778745.